Literature DB >> 7531916

Cellular tropism of human T-cell leukemia virus type II is enlarged to B lymphocytes in patients with high proviral load.

C Casoli1, A Cimarelli, U Bertazzoni.   

Abstract

To establish the in vivo cellular tropism of human T-cell leukemia virus type II (HTLV-II) in peripheral blood, subpopulations of mononuclear cells isolated from patients with a history of drug abuse and with high proviral load were analyzed by polymerase chain reaction for the presence of the proviral sequences. After purification of cellular subsets by immunomagnetic fractionation of blood cells of an infected patient, HTLV-II DNA was detected in CD4+ and CD8+ T-cells as well as in CD19+ B-cells. A positive PCR signal was obtained for purified B-cells also at limiting dilutions. This observation was confirmed by purifying the B-cell fraction by a two-step immunomagnetic procedure from the peripheral blood of another patient with very high HTLV-II copy number and quantifying the B-cell proviral load by means of competitive PCR. A proviral copy number of 90/100 B-cells was found, demonstrating that the great majority of these cells were infected by HTLV-II in this subject. The results indicate that HTLV-II has a broad host range in some infected individuals, showing an enlargement of cellular tropism to B lymphocytes and suggesting that this expression is associated with an increase in proviral load.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531916     DOI: 10.1006/viro.1995.1036

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

Authors:  J C Twizere; P Kerkhofs; A Burny; D Portetelle; R Kettmann; L Willems
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.

Authors:  Giovanna Tosi; Elisabetta Pilotti; Lorenzo Mortara; Andrea De Lerma Barbaro; Claudio Casoli; Roberto S Accolla
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

3.  Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo.

Authors:  G Feuer; J K Fraser; J A Zack; F Lee; R Feuer; I S Chen
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy.

Authors:  G Zehender; L Meroni; S Varchetta; C De Maddalena; B Cavalli; M Gianotto; A B Bosisio; C Colasante; G Rizzardini; M Moroni; M Galli
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression.

Authors:  M Giacomo; E G Franco; C Claudio; C Carlo; D A Anna; D Anna; F Franco
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

6.  Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication.

Authors:  Chiara Orlandi; Greta Forlani; Giovanna Tosi; Roberto S Accolla
Journal:  J Transl Med       Date:  2011-07-07       Impact factor: 5.531

7.  Clonality of HTLV-2 in natural infection.

Authors:  Anat Melamed; Aviva D Witkover; Daniel J Laydon; Rachael Brown; Kristin Ladell; Kelly Miners; Aileen G Rowan; Niall Gormley; David A Price; Graham P Taylor; Edward L Murphy; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2014-03-13       Impact factor: 6.823

Review 8.  Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors.

Authors:  Robert Harrod
Journal:  Retrovirology       Date:  2019-09-06       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.